China’s MabPlex raises $59m Series A

Founded in 2013, MabPlex offers biologics development and manufacturing services for global drug companies from the pre-clinical stage to commercial launch. Focus areas include antibody-drug conjugates and monoclonal antibodies (mAb), which are used to treat cancer. The company also provides management services to ensure drugs comply with the latest regulatory standards in the US, Europe, and China.

MabPlex has provided CDMO solutions for dozens of drug companies and realized more than 10 investigational new drug applications in the US and Australia in 2018. The company has recently opened R&D centers in San Diego and Shanghai in support of an existing manufacturing factory in Shandong. It currently owns 50,000 square meters factory space for manufacturing drugs.

“We have the vision to helping biopharmaceutical companies to accelerate their pace for R&D on drugs and reduce their manufacturing cost. We are one of the few Chinese start-ups that have established a one-stop services platform for companies engaged with big molecule drugs. This round of funding will largely improve our capacity,” said Jianmin Fang, chairman of the MabPlex.

Investment in CDMOs in China has expanded in recent years due to a lack of manufacturing facilities for early-stage drug developers globally and loosened regulatory requirements. Other players in this space include WuXi AppTech, which used to trade in the US before being privatized and re-listed in Shanghai and Hong Kong.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Greater China
• Healthcare
• Early-stage
• China
• Shenzhen Capital Group
• Pharmaceuticals